what is glp -1 GLP-1 PDB-101: Molecule of the Month:

The problem with them is that you don't know exactly what is in them

The progression from single to dual to triple agonism represents genuine innovation, not marketing hype

An early divergence of the time-to-first-event curves within three months of treatment initiation in SELECT means that the onset of semaglutides cardiovascular benefits preceded most of the achieved weight loss or other changes to cardiometabolic risk factors [91]

An analysis by Prime Therapeutics found that only 27% of people taking GLP-1 drugs were still taking the medication a year later due to side effects or the cost of prescriptions

Patients with missing demographic data (age or sex), type 1 DM, 30, missing baseline eGFR data, and those with a follow-up period 50%, and progression to ESKD with dialysis

touchREV Endocrinol 2022